Dianthus Therapeutics, Inc. /DE/ Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent of 13.40% for the 12-month period ending 2017-12-31, per its 10-K filed 2020-03-03.
Discontinued › Expense Statement
us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate · last filed 2020-03-03
- Dianthus Therapeutics, Inc. /DE/ effective income tax rate reconciliation, change in enacted tax rate, percent for fiscal 2017 was 13.40%.
| Period end | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent 12 month |
|---|---|
| 2017-12-31 | 13.40% 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |